An Open-Label Exploratory Phase 2/3 Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer
Phase of Trial: Phase II/III
Latest Information Update: 16 Dec 2018
At a glance
- Drugs Nivolumab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms CheckMate 9X8
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 22 Feb 2018 Planned End Date changed from 13 Aug 2022 to 18 Aug 2022.
- 22 Feb 2018 Planned primary completion date changed from 11 Aug 2021 to 16 Aug 2021.
- 22 Feb 2018 Status changed from not yet recruiting to recruiting.